Best Gold Stocks To Buy For 2018


If youre in your 20s or 30s, this article is aimed squarely at you. If youre older, I want you to give it to a young person. Youll be doing them a huge favor.

Investors in their 20s have a golden opportunity to start out right. Doing so can literally be worth millions of dollars.

(Disclosure: I dont know your parents. But I know thousands of adult investors, and Im very confident of this: If you take my advice in the following seven steps, youll be more successful than the vast majority of investors in your parents generation.)

Best Gold Stocks To Buy For 2018: Enerplus Corporation(ERF)


Advisors’ Opinion:

  • [By Money Morning News Team]

    Enerplus Corp. (NYSE: ERF) is a $2.1 billion oil company based in Calgary and trades on both the NYSE and Toronto Stock Exchange. ERF primarily produces crude oil in the Bakken fields in North Dakota and Western Canada.

Best Gold Stocks To Buy For 2018: Porter Bancorp Inc.(PBIB)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of PATRIOT FINANCIAL PARTNERS GP, LP’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=PATRIOT+FINANCIAL+PARTNERS+GP%2C+LP


    These are the top 5 holdings of PATRIOT FINANCIAL PARTNERS GP, LPBanc of California Inc (BANC) – 2,850,564 shares, 27.82% of the total portfolio. Guaranty Bancorp (GBNK) – 1,891,767 shares, 23.36% of the total portfolio. Shares reduced by 19.22%Meta Financial Group Inc (CASH) – 347,069 shares, 14.02% of the total portfolio. Sterling Bancorp (STL) – 1,048,980 shares, 11.07% of the total portfolio. Shares reduced by 16.01%MBT Financial Corp (MBTF) – 2,060,302 sha

Best Gold Stocks To Buy For 2018: Tandem Diabetes Care, Inc.(TNDM)


Advisors’ Opinion:

  • [By Lisa Levin]

    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares dropped 19 percent to $1.25. Tandem Diabetes Care priced its 18 million share offering at $1.25 per share.

  • [By Lisa Levin]

    Shares of Tandem Diabetes Care Inc (NASDAQ: TNDM) were down 58 percent to $2.25 after the company posted downbeat quarterly results.

    Cempra Inc (NASDAQ: CEMP) was down, falling around 59 percent to $7.69 after the FDA raised liver safety issues in its review of the company's experimental drug to treat community acquired pneumonia. Baird downgraded Cempra from Outperform to Underperform.

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Paul Ausick]

    Tandem Diabetes Care Inc. (NASDAQ: TNDM) dropped nearly 26% Thursday, to post a new 52-week low of $1.15 after closing at $1.55 on Wednesday. The stock’s 52-week high is $11.30. Volume was more than 20 times the daily average of around 290,000. The company announced an underwritten secondary offering of 18 million shares at $1.25 per share.

Leave a Reply

Your email address will not be published. Required fields are marked *